<DOC>
	<DOCNO>NCT00751205</DOCNO>
	<brief_summary>This study investigate safety efficacy Acetyl-L-Carnitine compare safety efficacy placebo ( inactive ) tablet prevention Sagopilone-induced peripheral neuropathy . Patients receive intravenous infusion sagopilone 3 hour day 1 3-weeks cycle . Treatment Sagopilone give long patient benefitting . In addition patient receive ALC placebo , start 1 week first sagopilone infusion end 30-33 day last infusion sagopilone . Safety determine laboratory evaluation . Efficacy ALC determine incidence grade peripheral neuropathy result patient questionnaire . Efficacy combination ALC Sagopilone determine tumor response .</brief_summary>
	<brief_title>Prevention Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine ( ALC )</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>Males female age &gt; /= 18 year Epithelial ovarian , peritoneal cavity Fallopian tube cancer ( except mucinous clear cell tumor ) Adenocarcinoma prostate At least 1 unidimensional measurable lesion ( suitable RECIST evaluation ) patient without measurable disease , CA 125 level &gt; /= 2 time upper limit normal ( ULN ) within 3 month confirm within 2 week prior first infusion ( ovarian cancer ) PSA value &gt; /= 5 ng/mL ( HRPC ) . Progression disease ( HRPC ) despite adequate androgeninhibiting hormone therapy . Progression disease ( Ovarian Cancer ) symptomatic relapse previous therapy ( elevate CA125 level alone insufficient inclusion ) WHO performance status 0 1 No clinical residual neuropathy ( CTCAE Grade 0 baseline ) Adequate recovery previous surgery , radiation , chemotherapy ( exclude alopecia ) Adequate function major organ system . Survival expectation =3 month Histologically cytologically prove : 1 . Epithelial ovarian , peritoneal cavity Fallopian tube cancer ( except mucionous cell tumor clear cell tumor clear cell component &gt; 33 % ) Symptomatic brain metastasis require whole brain irradiation Any concomitant malignancy : following exception allow : Nonmelanoma skin cancer , Carcinoma situ cervix , Malignancy definitive treatment &gt; /= 5 year ago without relapse . Diabetes mellitus ( even control special diet ) History chronic hepatitis B C , know HIV infection Seizure disorder require medication ( steroids antiepileptic ) Inability swallow oral medication Prior treatment epothilones Concomitant use neurotoxic drug Concomitant use compound potentially positive effect towards symptom neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Peripheral Neuropathy</keyword>
	<keyword>Prostate Carcinoma</keyword>
	<keyword>Ovarian Carcinoma</keyword>
</DOC>